A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992)

  • McLaren, Cameron (Primary Chief Investigator (PCI))
  • Liow, Elizabeth (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA HREC Reference Number: Austin Health ref DT 61492/2020
NMA SSA Reference Number: SSA/61492/MonH-2020-220875(v1)
Monash Health Reference: RES-20-0000-479X
Effective start/end date23/07/2022/07/25


  • clinical trial
  • phase 3 study
  • treatment efficacy
  • treatment safety
  • bladder cancer